The Biosimilar Contract Manufacturing Market is expanding through investments in manufacturing capacity and international outsourcing partnerships. North America held more than 45% of the global market in 2024, while Europe accounted for approximately 30%.

Asia-Pacific is emerging as a particularly attractive manufacturing region because of competitive production costs, expanding biotechnology infrastructure, and growing pharmaceutical capabilities. India is one example, with its biosimilar contract manufacturing market projected to reach USD 1.65 billion by 2033.

Major participants include Samsung Biologics, Lonza Group, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Catalent, WuXi Biologics, Roche, Amgen, and Sandoz.

Recent industry activity also demonstrates the continued importance of long-term manufacturing partnerships. For example, Aurigene Pharmaceutical Services announced a long-term manufacturing and supply agreement involving biologics and other products, highlighting continued outsourcing demand for specialized pharmaceutical production.

As biosimilar pipelines expand, pharmaceutical companies are expected to increasingly rely on contract manufacturers for scalable, compliant, and cost-efficient production. Advances in bioprocessing, analytical technologies, automation, and single-use manufacturing systems should further strengthen the market's long-term growth prospects.